A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells
Status:
Withdrawn
Trial end date:
2012-10-19
Target enrollment:
Participant gender:
Summary
Human Immunodeficiency Virus (HIV) infection is permanently established by integrating a
deoxyribonucleic acid (DNA) copy into the human chromosome, a step also necessary to complete
the Human Immunodeficiency Virus (HIV)replication cycle. Standard treatment of HIV infection
suppresses Human Immunodeficiency Virus (HIV)replication and has not been able to eliminate
Human Immunodeficiency Virus (HIV)from an infected person because of the integrated Human
Immunodeficiency Virus (HIV). Raltegravir (RAL), the first approved antiretroviral (ARV) in a
new class called integrase inhibitors, works by preventing integration of Human
Immunodeficiency Virus (HIV). For participants with Human Immunodeficiency Virus (HIV)who
have never taken antiretroviral medications, this research study will test whether
Raltegravir (RAL), a recommended first-line ARV, can eliminate Human Immunodeficiency Virus
(HIV)from key immune system cells.
Phase:
Phase 4
Details
Lead Sponsor:
Community Research Initiative of New England
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Raltegravir Potassium Tenofovir